EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort

Akira Ohtsu, Yusuke Otani, Seiji Arai, Anna Rogachevskaya, Vanessa D Chin, Shinichi Toyooka, Kazuhiro Suzuki, Wenyi Wei, Atsushi Tanaka

International Journal of Clinical Oncology · 2026-05 · 31 (5) · 868-877

DOI: 10.1007/s10147-026-03005-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 08.03.2026. Verfasst von Akira Ohtsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, the Japan Society for the Promotion of Science (JSPS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic bladder urothelial carcinoma has poor survival, and large comparative genomic studies using uniform targeted sequencing of paired primary and metastatic lesions remain limited. We compared gene- and pathway-level alterations between primary and metastatic tumors Methods We analyzed 2,880 bladder urothelial carcinoma samples (2,305 primary; 575 metastatic) from 2,343 patients profiled with MSK-IMPACT. Somatic mutations and copy number alterations were integrated per gene and compared between primary and metastatic samples in the full cohort and in a paired subset using standard statistical tests.

Results

Primary and metastatic samples showed broadly similar driver landscapes. In the full cohort, KDM6A, FGFR3, STAG2, and ERCC2 were more frequently altered in primary tumors, whereas no individual genes were enriched in metastases; these differences were not significant in paired analyses. At the pathway level, TP53 pathway alterations were relatively more frequent in metastases, while DNA damage response alterations were enriched in primary tumors; other pathways showed comparable alteration rates. Apoptosis-focused analyses identified no significant gene-level differences, but suggested a trend toward higher alteration rates in the TP53 pathway and apoptosis regulators in metastases.

Conclusion

Primary and metastatic lesions of bladder urothelial carcinoma show broadly similar gene- and pathway-level alteration profiles on targeted DNA sequencing. TP53 pathway and apoptosis-related alterations are modestly more frequent in metastases, consistent with impaired stress responses and apoptosis evasion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansGenomicsMutationNeoplasm MetastasisFemaleMaleTumor Suppressor Protein p53Cohort StudiesDNA Copy Number VariationsHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

TP53 pathwayBladder urothelial carcinomaDNA damage responseMetastasisPrimaryTargeted next-generation sequencing

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
  • Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan. a-seiji@gunma-u.ac.jp.

Förderung

  • NCI NIH HHS
  • the Japan Society for the Promotion of Science (JSPS)

Zitieren

APA

Ohtsu, A., Otani, Y., Arai, S., Rogachevskaya, A., Chin, V. D., Toyooka, S., Suzuki, K., Wei, W., & Tanaka, A. (2026). Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort. International Journal of Clinical Oncology, 31(5), 868-877. https://doi.org/10.1007/s10147-026-03005-2

Vancouver

Ohtsu A, Otani Y, Arai S, Rogachevskaya A, Chin VD, Toyooka S, et al. Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort. International Journal of Clinical Oncology. 2026;31(5):868-877. doi:10.1007/s10147-026-03005-2

BibTeX
@article{Ohtsu2026,
  author = {Ohtsu, Akira and Otani, Yusuke and Arai, Seiji and Rogachevskaya, Anna and Chin, Vanessa D and Toyooka, Shinichi and Suzuki, Kazuhiro and Wei, Wenyi and Tanaka, Atsushi},
  title = {Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {5},
  pages = {868--877},
  doi = {10.1007/s10147-026-03005-2}
}
Kostenlos starten →